Dr. Thomas Scullion discusses how to leverage NHP exploratory toxicology studies to guide and explore lead optimization, dosing paradigms, and future GLP studies.
The clinical toxicity of immunotherapy can be unpredictable, often deviating from preclinical research in rodent models. On the other hand, in-vivo research using NHP models to assess immunotoxicity is far more translational, much of the risk out of clinical trials.
In this webinar sponsored by CrownBio, Dr. Thomas Scullion will discuss how to leverage NHP exploratory toxicology studies to inform lead optomization, dosing paradigms and GLP studies. Dr. Scullion will also highlight the translational relevance of NHP models for immunotoxicity research.
Presenters
Thomas Scullion
Dr. Thomas Scullion has extensive experience guiding clients’ early drug discovery work through to clinical trials. At CrownBio, he specializes in pharmacology, toxicology, and bioanalytics using translational animal models. Thomas holds a PhD in Neuropharmacology, and previously worked at Symbiosis Pharmaceutical Services Limited and Charles River Laboratories.
Sponsor
